Advertisement
Research Article

Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia

  • Sarosh Rana mail,

    srana1@bidmc.harvard.edu

    Affiliations: Division of Maternal Fetal Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Ana Sofia Cerdeira,

    Affiliations: Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America, Gulbenkian Programme for Advanced Medical Education, Lisbon, Portugal

    X
  • Julia Wenger,

    Affiliation: Division of Nephrology/Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Saira Salahuddin,

    Affiliation: Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Kee-Hak Lim,

    Affiliations: Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America, Boston Maternal Fetal Medicine Group, Boston, Massachusetts, United States of America

    X
  • Steven J. Ralston,

    Affiliations: Division of Maternal Fetal Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Ravi I. Thadhani,

    Affiliation: Division of Nephrology/Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • S. Ananth Karumanchi

    Affiliations: Division of Maternal Fetal Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America, Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America

    X
  • Published: October 26, 2012
  • DOI: 10.1371/journal.pone.0048259
  • Published in PLOS ONE

About the Authors

Sarosh Rana, Steven J. Ralston, S. Ananth Karumanchi
Division of Maternal Fetal Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America
Sarosh Rana, Saira Salahuddin, Kee-Hak Lim, Steven J. Ralston, S. Ananth Karumanchi
Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America
Ana Sofia Cerdeira, S. Ananth Karumanchi
Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America
Ana Sofia Cerdeira
Gulbenkian Programme for Advanced Medical Education, Lisbon, Portugal
Julia Wenger, Ravi I. Thadhani
Division of Nephrology/Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
Kee-Hak Lim
Boston Maternal Fetal Medicine Group, Boston, Massachusetts, United States of America
S. Ananth Karumanchi
Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America

Corresponding Author

Email: srana1@bidmc.harvard.edu

Competing Interests

The authors have read the journal's policy and have the following conflicts: Dr. Karumanchi is co-inventor on multiple patents (USPTO #7,740,849, #7,407,658, #7,335,362, #7,344,892) related to the use of angiogenic markers for the diagnosis, prediction and therapy of preeclampsia). Dr. Karumanchi reports having served as a consultant to Roche and Beckman Coulter and has financial interest in Aggamin LLC. Dr. Thadhani is a co-inventor on a patent (USPTO #7,344,892) related to the use of angiogenic proteins for the prediction of preeclampsia and has financial interest in Aggamin LLC.

Author Contributions

Conceived and designed the experiments: SR ASC SS RT SAK. Performed the experiments: SR SS. Analyzed the data: JW RT. Contributed reagents/materials/analysis tools: RT SAK. Wrote the paper: SR ASC JW KHL SJR RT SAK. Consented and collected all samples: SS.